For laboratory research only
Compare Sermorelin research suppliers
Listings now default to lowest tracked price per mg. The highlighted price badge is a catalog-price signal only, not a quality, safety, or documentation ranking.
The document count covers six basic checks. “Not found” means we could not confirm it from the public records we reviewed—not that the testing never happened.
Affiliate disclosure: Some links may earn PDD a commission. Affiliate status does not change what we report or how suppliers are ordered.
Elite Research Labs
6 of 6 fields documentedChecked 12 days agoSermorelin (10 mg)
Exact name catalog match · Affiliate relationship · Price badge is not an overall recommendation
Listed price
$46.74
$4.67 per mg
In stock
Aero Peptides
4 of 6 fields documentedPossibly outdatedSermorelin (10 mg)
Exact name catalog match · Affiliate relationship
Listed price
$64.99
$6.50 per mg
In stock
Ascension Peptides
2 of 6 fields documentedPossibly outdatedSermorelin (10 mg)
Exact name catalog match · Affiliate relationship
Listed price
$72.00
$7.20 per mg
In stock
Eppix Labs
5 of 6 fields documentedReview recommendedSermorelin (5 mg)
Exact name catalog match · No active affiliate relationship
Listed price
$39.99
$8.00 per mg
In stock
PS Peptides
5 of 6 fields documentedPossibly outdatedSermorelin (10 mg)
Exact name catalog match · Affiliate relationship
Listed price
$79.99
$8.00 per mg
Est. with PDD10: $71.99
$7.20/mg
In stock
How Sermorelin is used in research
Sermorelin corresponds to the biologically active N-terminal portion of GHRH and stimulates pituitary growth-hormone release in experimental and clinical contexts.
A prior FDA-approved product history is often cited, but discontinued or historical product status must not be used to imply that current research-vendor materials are approved drugs.
Evidence map
Research stage matters. Findings from one model should not be silently promoted to another.
Laboratory
Receptor and pituitary studies characterize GHRH signaling.
Animal
Endocrine models examine pulsatility and pituitary responses.
Human
Clinical and diagnostic history exists, including a previously approved product.
What the evidence does not establish
Historical clinical use does not establish the quality, legality, or equivalence of a current unapproved preparation.
Study findings also do not authenticate a supplier’s material. Biological plausibility, a familiar name, or a published paper cannot substitute for lot-specific identity and quality evidence.
Analytical and documentation checks
The test plan should match the exact molecule, modification, and research question.
- Confirm the 29-residue sequence and acetate or other salt form.
- Evaluate deamidation, oxidation, and truncation where relevant.
- Do not conflate a research COA with finished-drug manufacturing controls.
At minimum, connect the product name, sequence, sample identifier, lot, report, method, expected result, and observed result. Record untested attributes as “not reported,” not as assumed passes.
Build the documentation record
Regulatory status
A sermorelin product previously held FDA approval and was discontinued; current product status must be checked in Drugs@FDA. Research materials do not inherit the former approval.
Regulatory status can change and attaches to specific products and jurisdictions. Verify current official records before publishing, procuring, or relying on a status claim.
Primary sources and official records
Use these records as starting points, then assess the exact model, test article, methods, and date:
Peptide Due Diligence Research Brief
Follow the evidence, not the headline.
Receive new evidence maps, documentation guides, and material corrections as the directory expands.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free checklist.